SANUWAVE Health Inc

Análisis de la acción SANUWAVE Health Inc (SNWV)

$2.210

-0.040 (-1.79%)Al cierre

Loading chart…
Máximo
2.650
Apertura
2.340
Precio medio ponderado por volumen
2.32
Volumen
361.26K
Capitalización
—
Mínimo
2.105
Importe
838.71K
EV/EBITDA, TTM
-141.67

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.

sanuwave.com

Análisis de IA of SANUWAVE Health Inc (SNWV)

Vender

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

Métricas de valoración

El PER previsto actual de SANUWAVE Health Inc (SNWV) es 18.25, frente a su media de 5 años de 21.60.

PER previsto

Valor razonable
Media 5A P/E
21.60
P/E actual
18.25
Sobrevalorada
37.29
Infravalorada
5.92

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
-5.23
EV/EBITDA actual
-141.67
Sobrevalorada
58.87
Infravalorada
-69.32

Precio/ventas previsto

Infravalorado
Media 5A P/S
2.63
P/S actual
0.30
Sobrevalorada
4.90
Infravalorada
0.35

Escenarios de precio de Alphio AI para SNWV

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%SNWV

$40.32

Precio del escenario

B

Base

Base · 50%SNWV

$36.11

Precio del escenario

B

Bajista

Bajista · 25%SNWV

$28.03

Precio del escenario

Cronología de eventos

2026-11-05 (ET)

10:01:00

SANUWAVE Health Inc Trading Resumes

10:00:00

SANUWAVE Health Inc Trading Halted Due to Volatility

2026-07-13 (ET)

17:00:00

Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M

2026-05-12 (ET)

17:10:00

Sanuwave Reports Q1 Revenue of $9.6M

17:10:00

Sanuwave Health Maintains FY26 Revenue View of $51M-$55M

Noticias

Preguntas frecuentes sobre SNWV, respondidas por Alphio AI

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar